Controversial pharma company Mylan offered several states participating in Medicaid purchasing pools discounts on the EpiPen if they could ensure competitors’ products weren’t readily available to patients, according to a new report that raises additional concerns that the drugmaker engaged in anti-competitive practices as it raised the price of the life-saving drug nearly 400% in just 10 years. [More]